上尿路尿路上皮癌Slit引导配体3的表达与临床病理特征以及预后的关系

doi:10.3969/j.issn.1006-7795.2020.03.007

首都医科大学学报 ›› 2020, Vol. 41 ›› Issue (3): 354-359.doi: 10.3969/j.issn.1006-7795.2020.03.007

上尿路尿路上皮癌Slit引导配体3的表达与临床病理特征以及预后的关系

吴西抗¹, 王跃², 贺慧颖¹

1. 北京大学医学部病理系北京大学第三医院病理科, 北京 100191;
2. 北京大学首钢医院病理科, 北京 100144

收稿日期:2020-02-10 出版日期:2020-06-21 发布日期:2020-06-17
通讯作者: 贺慧颖 E-mail:huiyinghe@bjmu.edu.cn
基金资助:
国家自然科学基金面上项目（81872382），北京市重点学科基础医学学科建设项目（BNU20110254）。

Expression and significance of Slit guidance ligand 3 in upper tract urothelial carcinoma

Wu Xikang¹, Wang Yue², He Huiying¹

1. Department of Pathology, School of Basic Medical Sciences, Third Hospital, Peking University Health Science Center, Beijing 100191, China;
2. Department of Pathology, Peking University Shougang Hospital, Beijing 100144, China

Received:2020-02-10 Online:2020-06-21 Published:2020-06-17
Supported by:
This study was supported by National Natural Science Foundation of China (81872382), Leading Academic Discipline Project of Beijing Education Bureau (BMU20110254).

摘要/Abstract

摘要： 目的观察Slit引导配体3（Slit guidance ligand 3，Slit3）在上尿路尿路上皮癌（upper tract urothelial carcinoma，UTUC）中的表达及其与UTUC临床病理特征以及预后的关系。方法采用免疫组织化学方法检测Slit3在UTUC中的表达，并运用相关统计学方法分析Slit3表达与UTUC临床病理特征（包括患者年龄、性别、组织学分级、分期和大片坏死等）以及预后的关系。结果在UTUC患者中，Slit3表达随着肿瘤组织学分级和分期的增高而减低（P=0.014和P=0.006），Slit3还与肿瘤膀胱复发具有相关性（P=0.011）。在单因素生存分析中，Slit3低表达与UTUC患者的较短无病生存期和癌特异性生存期均相关（P=0.006，P=0.015），但在多因素生存分析中无统计学意义（P=0.213，P=0.332）。结论 Slit3的低表达与肿瘤高分级、高分期以及膀胱复发相关，但不影响UTUC的预后。

关键词: 上尿路尿路上皮癌, Slit引导配体3, 免疫组织化学, 预后

Abstract: Objective To observe the expression of Slit guidance ligand 3(Slit3) in upper tract urothelial carcinoma (UTUC) and its relationship with the clinicopathological features and prognosis of UTUC patients. Methods The expression of Slit3 in UTUC was detected by immunohistochemical method, and the association of Slit3 expression with the clinicopathological features of UTUC (including age, sex, histological grade, stage and extensive necrosis, etc.) and prognosis were analyzed. Results For UTUC patients, the Slit3 expression decreased with the increased histological grade and tumor stage (P=0.014, P=0.006). Slit3 was also associated with the bladder recurrence (P=0.011). In univariate survival analysis, the lower Slit3 expression was associated with the shorter disease-free survival and cancer-specific survival in UTUC patients (P=0.006, P=0.015), but it was not statistically significant in multivariate analysis (P=0.213, P=0.332). Conclusion Slit3 is likely to be involved in the progression of UTUC. The lower expression of Slit3 is associated with the higher tumor grade, stage and bladder recurrence rate, however, Slit3 is not an independent prognostic factor for UTUC patients.

Key words: upper tract urothelial carcinoma, Slit guidance ligand 3, immunohistochemistry, prognosis

中图分类号:

R737

吴西抗, 王跃, 贺慧颖. 上尿路尿路上皮癌Slit引导配体3的表达与临床病理特征以及预后的关系[J]. 首都医科大学学报, 2020, 41(3): 354-359.

Wu Xikang, Wang Yue, He Huiying. Expression and significance of Slit guidance ligand 3 in upper tract urothelial carcinoma[J]. Journal of Capital Medical University, 2020, 41(3): 354-359.

参考文献

[1] Rouprêt M, Babjuk M, Compêrat E, et al. European Association of Urology Guidelines on upper urinary tract Urothelial cell carcinoma:2015 update[J]. Eur Urol, 2015, 68(5):868-879.
[2] Rouprêt M, Babjuk M, Compêrat E, et al. European Association of Urology Guidelines on upper urinary tract urothelial carcinoma:2017 update[J]. Eur Urol, 2018, 73(1):111-122.
[3] Babjuk M, B öhle A, Burger M, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder:update 2016[J]. Eur Urol, 2017, 71(3):447-461.
[4] Chung S D, Yu H J, Chueh S C. Re:Ching-Chia Li, Tu-Hao Chang, Wen-Jeng Wu, et al. Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in taiwanese patients. Eur Urol 2008;54:1127-35[J]. Eur Urol, 2009, 55(4):e69-70; author reply e71.
[5] Chen X P, Xiong G Y, Li X S, et al. Predictive factors for worse pathological outcomes of upper tract urothelial carcinoma:experience from a nationwide high-volume centre in China[J]. BJU Int, 2013, 112(7):917-924.
[6] Guan H, Wei G, Wu J, et al. Down-regulation of miR-218-2 and its host gene SLIT3 cooperate to promote invasion and progression of thyroid cancer[J]. J Clin Endocrinol Metab, 2013, 98(8):E1334-1344.
[7] Denk A E, Braig S, Schubert T, et al. Slit3 inhibits activator protein 1-mediated migration of malignant melanoma cells[J]. Int J Mol Med, 2011, 28(5):721-726.
[8] Yu H, Gao G Z, Jiang L, et al. Decreased expression of miR-218 is associated with poor prognosis in patients with colorectal cancer[J]. Int J Clin Exp Pathol, 2013, 6(12):2904-2911.
[9] Paner G P, Stadler W M, Hansel D E, et al. Updates in the eighth edition of the tumor-node-metastasis staging classification for urologic cancers[J]. Eur Urol,2018,73(4):560-569.
[10] Moch H, Cubilla A L, Humphrey P A, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A:renal, penile, and testicular tumours[J]. Eur Urol, 2016, 70(1):93-105.
[11] Rubin M A, Dunn R, Strawderman M, et al. Tissue microarray sampling strategy for prostate cancer biomarker analysis[J]. Am J Surg Pathol, 2002, 26(3):312-319.
[12] Lee H Y, Chen Y J, Li C C, et al. Deduction of novel genes potentially involved in upper tract urothelial carcinoma using next-generation sequencing and bioinformatics approaches[J]. Int J Med Sci, 2019, 16(1):93-105.
[13] Nüsslein-Volhard C, Wieschaus E, Kluding H. Mutations affecting the pattern of the larval cuticle inDrosophila melanogaster:I. Zygotic loci on the second chromosome[J]. Wilehm Roux Arch Dev Biol, 1984, 193(5):267-282.
[14] Rothberg J M, Hartley D A, Walther Z, et al. Slit-an Egf-homologous locus of Drosophila-Melanogaster involved in the development of the embryonic central nervous-system[J]. Cell, 1988, 55(6):1047-1059.
[15] Tong M, Jun T, Nie Y, et al. The role of the Slit/Robo signaling pathway[J]. J Cancer, 2019, 10(12):2694-2705.
[16] Liu J, Zhang L, Wang D, et al. Congenital diaphragmatic hernia, kidney agenesis and cardiac defects associated with Slit3-deficiency in mice[J]. Mech Dev, 2003, 120(9):1059-1070.
[17] Zhang B, Dietrich U M, Geng J G, et al. Repulsive axon guidance molecule Slit3 is a novel angiogenic factor[J].Blood, 2009, 114(19):4300-4309.
[18] Ng L, Chow A K M, Man J H W, et al. Suppression of Slit3 induces tumor proliferation and chemoresistance in hepatocellular carcinoma through activation of GSK3beta/beta-catenin pathway[J]. BMC Cancer, 2018, 18(1):621.
[19] Zhang C, Guo H, Li B, et al. Effects of Slit3 silencing on the invasive ability of lung carcinoma A549 cells[J]. Oncol Rep, 2015, 34(2):952-960.
[20] Wei R, Ye X, Zhao Y, et al. MicroRNA-218 inhibits the cell proliferation and migration in clear cell renal cell carcinoma through targeting cancerous inhibitor of protein phosphatase 2A[J]. Oncol Lett, 2019, 17(3):3211-3218.
[21] Kim M, Kim J H, Baek S J, et al. Specific expression and methylation of SLIT1, SLIT2, SLIT3, and miR-218 in gastric cancer subtypes[J]. Int J Oncol, 2016, 48(6):2497-2507.
[22] Moss T J, Qi Y, Xi L, et al. Comprehensive genomic characterization of upper tract urothelial carcinoma[J]. Eur Urol, 2017, 72(4):641-649.

上尿路尿路上皮癌Slit引导配体3的表达与临床病理特征以及预后的关系

Expression and significance of Slit guidance ligand 3 in upper tract urothelial carcinoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王荣荣, 田俊萍. 急性冠脉综合征患者血清钙与心血管预后的关系[J]. 首都医科大学学报, 2023, 44(1): 154-160.
[2]	贾静, 陈文明, 李燕郴. 多发性骨髓瘤伴中枢侵犯临床特征及预后分析[J]. 首都医科大学学报, 2023, 44(1): 161-166.
[3]	李颖, 陈彪, 王乃利, 郝欣平. 人体内耳冰冻切片免疫组织化学染色技术探讨[J]. 首都医科大学学报, 2022, 43(6): 905-910.
[4]	于天宇, 姜世敏, 高红梅, 邹古明, 李文歌. 糖尿病肾病慢性肾脏病4期患者肾脏临床及病理因素与预后的关系[J]. 首都医科大学学报, 2022, 43(5): 707-712.
[5]	郭康林, 程一春, 葛树旺, 徐钢. IgA肾病国际风险预测工具在中国人群中的预测效果评价[J]. 首都医科大学学报, 2022, 43(5): 713-719.
[6]	赵越, 阮祥燕, 程姣姣, 谷牧青, 许新, 王月姣. 乳腺癌中PGRMC1表达与临床病理参数的相关性[J]. 首都医科大学学报, 2022, 43(3): 350-356.
[7]	谷强, 余孝君, 张津. 高龄与中低龄老年轻型缺血性脑卒中临床特点及预后分析[J]. 首都医科大学学报, 2022, 43(3): 474-479.
[8]	周巧云, 黄晓武, 夏恩兰, 赵玉婷, 黄睿. 子宫动脉栓塞后宫腔粘连的生殖结局分析[J]. 首都医科大学学报, 2022, 43(3): 490-494.
[9]	苗祖霈, 张迎花, 肖克令, 司瑾, 张浩宇, 李静. 肥胖程度对急性ST段抬高型心肌梗死患者预后的影响[J]. 首都医科大学学报, 2022, 43(2): 192-198.
[10]	孙婧, 史幼梧, 贾军, 杨颖, 孙志伟, 杜丰, 余靖, 肖艳洁, 张晓东. 血液炎症相关指标在晚期胰腺癌中的预后价值[J]. 首都医科大学学报, 2022, 43(2): 299-304.
[11]	刘洋, 吴玉梅, 何玥, 樊蓓, 王雁, 赵辉, 王明. ⅠB期子宫颈癌国际妇产科联盟2018新分期的合理性验证及评估[J]. 首都医科大学学报, 2021, 42(6): 1026-1032.
[12]	王莉, 张国军. 血清神经元特异性烯醇化酶与外伤性脑损伤患者及临床特征的关系[J]. 首都医科大学学报, 2021, 42(5): 715-720.
[13]	来璇, 张爱华. 代谢综合征对慢性肾脏病患者生存预后的影响[J]. 首都医科大学学报, 2021, 42(4): 609-614.
[14]	王欣, 张俊璇, 高健, 石汉平. 免疫营养改善肿瘤患者预后[J]. 首都医科大学学报, 2020, 41(6): 1019-1024.
[15]	刘军, 曹庆飞, 叶雄俊, 陈伟男, 赵海岳, 佟明, 王银银, 黄晓波, 常智杰. CREPT在肾癌组织中的表达及其与预后的关系[J]. 首都医科大学学报, 2020, 41(4): 552-557.